Budesonide Oral Suspension (Eohilia) Official Insert Contents

Budesonide Oral Suspension (Eohilia) is a prescription drug specifically for the treatment of Eosinophilic Esophagitis (EoE). It is a topical anti-inflammatory corticosteroid. The drug acts locally on the esophageal mucosa to reduce the infiltration and activity of inflammatory cells, thereby improving patients' symptoms such as dysphagia, food obstruction, and retrosternal discomfort. Eohilia is suitable for children and adult patients aged 11 years and above. Clinical studies have shown that it can significantly relieve symptoms and improve the structure of the esophageal mucosa during 12 weeks of continuous treatment.

1. Indications and limitations of use

Eohilia is mainly used for the ongoing treatment of acidocytic esophagitis, especially for patients who still have symptoms despite other treatments. The official instructions clearly state that the course of drug treatment is limited to 12 weeks. The safety and effectiveness of long-term use beyond 12 weeks have not been fully established, so it is not recommended to extend the course of treatment on your own. In clinical practice, if the symptoms are not completely relieved, subsequent treatment options should be evaluated under the guidance of a professional physician, and the dosage or medication time should not be increased arbitrarily to avoid potential risks.

2. Recommended dosage and usage

The standard recommended dose is 2 mg each time, taken orally twice a day for 12 weeks. The drug is in the form of a suspension. After oral administration, it mainly acts on the surface of the esophageal mucosa, reducing systemic hormone exposure and reducing the risk of systemic side effects. The suspension should be shaken well when taking to ensure uniform dosage each time. In order to obtain the best effect, patients should strictly follow the dosage and medication frequency under the guidance of a doctor. Even if symptoms are relieved, the full course of treatment should be completed to ensure adequate repair of the esophageal mucosa.

3. Adverse reactions

In clinical trials,The most common adverse reactions of Eohilia include respiratory tract infection, gastrointestinal mucosal candida infection, headache, gastroenteritis, throat irritation, adrenal suppression, and erosive esophagitis. Although most adverse reactions are mild to moderate, long-term or inappropriate use may increase the risk of systemic corticosteroid side effects. Therefore, patients should closely monitor changes in symptoms during use. If persistent headaches, worsening swallowing, or other abnormalities occur, they should seek medical treatment in time.

4. Pharmacological effects

Budesonide is an anti-inflammatory corticosteroid with high glucocorticoid activity and weak mineralocorticoid effects, and it has a high affinity for the glucocorticoid receptor. Its intrinsic potency is approximately that of natural cortisol200 times that of prednisolone and 15 times that of prednisolone, it can effectively inhibit the activity of eosinophils and other inflammatory cells, reduce local inflammation of the esophagus, thereby improving the patient's swallowing function and quality of life. The formulation design of the oral suspension ensures high local concentration of the drug in the esophagus, low systemic absorption, and reduces the risk of systemic hormonal side effects.

5. Storage and precautions

Eohilia should be stored at 2℃-25℃ and avoid freezing to maintain drug stability and efficacy. Medications should be kept out of reach of children to prevent accidental ingestion. In addition, repeated use with other systemic corticosteroids should be avoided during drug use to avoid increasing the risk of side effects. Medications should be used strictly in accordance with the doctor's prescription, and do not increase the dose or extend the course of treatment on your own.

Reference materials:https://www.drugs.com